Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | EP300 | Q09472 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TK1 | P04183 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18081921 | 0.83 | HPGD (0.69) | MAPK1HPGDTK1 | |
| SCHEMBL18081900 | 0.83 | MAPK1 (0.54) | MAPK1HPGDCA12CA9 | |
| SCHEMBL18080405 | 0.83 | EP300 (0.39) | MAPK1HPGDEP300CA12CA9 | |
| SCHEMBL16631677 | 0.81 | MAPK1 (0.44) | MAPK1HPGDEP300TK1 | |
| SCHEMBL16631449 | 0.80 | MAPK1 (0.50) | MAPK1HPGDCA12CA9 | |
| SCHEMBL16631491 | 0.77 | HPGD (0.60) | MAPK1HPGDCA12CA9TK1 | |
| SCHEMBL16631396 | 0.75 | MAPK1 (0.55) | MAPK1HPGDTK1 | |
| SCHEMBL2183944 | 0.75 | MAPK1 (0.61) | MAPK1HPGDTK1 | |
| Ammonia Solution, Strong SCHEMBL4194711 | 0.73 | MAPK1 (0.59) | MAPK1HPGDTK1 | |
| SCHEMBL16631675 | 0.72 | MAPK1 (0.48) | MAPK1HPGDTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | MAPK1 4185/4885HPGD 3931/4885EP300 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.